Hematology Advisor

FLT3-ITD MRD Could Guide Gilteritinib Maintenance After HCT for AML FLT3-ITD measurable residual disease was linked to relapse risk for patients with AML, and the use of gilteritinib as maintenance therapy helped to reduce this risk.

FLT3-ITD MRD is associated with an increased risk of relapse among patients with acute myeloid #leukemia, and maintenance gilteritinib helps reduce this risk. Published in @bloodjournal.bsky.social.

bit.ly/3GLctpR

#AML #leusm

Data Support Use of Isatuximab via On-Body Injector, Researcher Says - Hematology Advisor “I believe IRAKLIA is going to allow us to use isatuximab in its subcu formulation with this OBI , maybe tomorrow or the day after, in our practice,” said Xavier Leleu, MD, PhD.

Subcutaneous isatuximab administered via an on-body injector appears to be as safe and effective as intravenous isatuximab in patients with R/R #multipleMyeloma. Presented at #EHA2025, covered by @cancertherapyadv.bsky.social.

Psychopathology Is Common Among Pediatric Patients With ALL Patients with high-risk and intermediate-risk ALL were significantly more likely to have a psychopathology than those with standard-risk ALL.

An increased prevalence of psychiatric comorbidities may be common in pediatric patients with acute #lymphoblasticleukemia. From @rarediseaseadvisor.bsky.social.

bit.ly/45mYuzL

#leusm #lymsm

Negative Family History in Severe Hemophilia A Leads to Delay in Diagnosis Patients without a family history of hemophilia are at risk of delayed diagnosis and poorer treatment outcomes.

A lack of a family history is an impediment to achieving a timely diagnosis in severe #hemophilia A and is associated with poorer treatment outcomes. From @rarediseaseadvisor.bsky.social.

Caregivers and HCPs May Benefit From Improved Information Sharing on Hemophilia in Children Researchers determined there is a need for standardized, centrally available, and tailored information on care for caregivers of young children with hemophilia.

A study of caregivers’ and #HCPs experiences has identified 3 main themes for unmet needs regarding #hemophilia information provision. The findings were published in @haemophilia.bsky.social.

bit.ly/4o7Uk6x

Data Support Use of Isatuximab via On-Body Injector, Researcher Says - Hematology Advisor “I believe IRAKLIA is going to allow us to use isatuximab in its subcu formulation with this OBI , maybe tomorrow or the day after, in our practice,” said Xavier Leleu, MD, PhD.

Subcutaneous isatuximab administered via an on-body injector appears to be as safe and effective as intravenous isatuximab in patients with R/R #multipleMyeloma. Presented at #EHA2025.

bit.ly/46jn1qB

Durable Platelet Response Seen With Rilzabrutinib in Patients With Persistent/Chronic ITP Researchers determined rilzabrutinib led to rapid and durable platelet response and demonstrated a favorable safety profile in heavily pretreated adults with persistent or chronic ITP.

In the phase 3 LUNA3 study, rilzabrutinib led to rapid and durable platelet response and demonstrated a favorable safety profile in heavily pretreated adults with persistent or chronic #ITP. Published in @bloodjournal.bsky.social.

bit.ly/46TuCfx

Durable Platelet Response Seen With Rilzabrutinib in Patients With Persistent/Chronic ITP Researchers determined rilzabrutinib led to rapid and durable platelet response and demonstrated a favorable safety profile in heavily pretreated adults with persistent or chronic ITP.

In the phase 3 LUNA3 study, rilzabrutinib led to rapid and durable platelet response and demonstrated a favorable safety profile in heavily pretreated adults with persistent or chronic #ITP. Published in @bloodjournal.bsky.social.

bit.ly/46TuCfx

Venetoclax Fails to Improve OS in Relapsed/Refractory Multiple Myeloma Researchers determined that adding venetoclax to bortezomib and dexamethasone failed to prolong OS among patients with relapsed/refractory MM.

The final analysis of the phase 3 BELLINI trial demonstrated that the addition of venetoclax to bortezomib and dexamethasone failed to prolong OS compared with placebo plus bortezomib and dexamethasone among patients with R/R #multipleMyeloma. Published in @thelancethaem.bsky.social

bit.ly/4lKNfqW

Psychological Stress Biomarker Levels Found Higher in Neuro-Oncology Caregivers Researchers found that C-reactive protein is a biomarker for psychological stress in caregivers of patients with primary malignant brain tumor. C-reactive protein levels were found to be a biomarker o...

C-reactive protein levels are found to be increased among #caregivers of persons with a primary malignant #braintumor, highlighting the role of this biomarker as an indicator of psychological stress. Published in @oncologynurseadv.bsky.social.

bit.ly/4lFdONA

Recurrent PCNSL Signaled by FLAIR Hyperintensity Without Enhancement Despite normal results on CSF fluid analysis, a stereotactic biopsy revealed PCNSL recurrence.

Researchers have reported a case of recurrent primary central nervous system #lymphoma that demonstrated only mild 18F-FDG PET uptake on relapse. From @rarediseaseadvisor.bsky.social.

bit.ly/4kz1o91

#PCNSL #lymsm

Cancer Drug Prices Continue to Rise, Outpacing Inflation The prices charged at the US launch of targeted cancer therapies have increased well above the rate of inflation every year since 2012.

The prices charged at the US launch of targeted #cancer therapies have increased well above the rate of inflation every year since 2012. Published in @jama.com and @cancertherapyadv.bsky.social.

bit.ly/4lRtzky

International Study Suggests SMIs, EMs Yield Benefit in Second-Line Treatment of TNKLs Researchers determined EMs and SMIs may yield optimal outcomes among patients with relapsed or refractory mature T- and natural killer–cell lymphomas.

A large consortium study suggests that the use of second-line EMs or SMIs may yield optimal outcomes among patients with R/R mature TNKLs.

bit.ly/4nPhFJL

#lymphoma #lymsm

Initiative Developed for Improving the Health Care Transition for Patients With SCD Researchers developed an initiative to improve heath care transition for patients with SCD.

An initiative aimed at improving the health care transition for young patients with #sickleCellDisease appeared to demonstrate success in reaching goals across a network of centers. Reported in @jamanetworkopen.com.

bit.ly/4lugVYY

#SCD

TyG Index Is a Valuable Prognostic Tool in Patients With DLBCL Patients in the low TyG index group had higher survival rates than those in the high TyG group, and this result was maintained across patient subgroups.

The TyG index is an accurate and useful tool for prognostic assessment in #DLBCL. Published in @frontiersin.bsky.social Endocrinology.

bit.ly/4lc8C3W

#lymsm

Low-Dose Nivolumab and Bendamustine Improves Outcomes for Pediatric R/R Hodgkin Lymphoma Combination therapy incorporating low-dose nivolumab and bendamustine led to favorable survival and complete remission outcomes.

The combination of low-dose nivolumab with bendamustine in treatment of children with high-risk R/R classical #HodgkinLymphoma appeared to be associated with favorable survival and response outcomes. Reported in @brjhaem.bsky.social.

bit.ly/407skpa

#lymsm

Lynozyfic Approved for Relapsed/Refractory Multiple Myeloma The FDA approved Lynozyfic (linvoseltamab-gcpt) for adults with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy.

The @fda.gov has granted accelerated approval to Lynozyfic™ for the treatment of adults with R/R #multipleMyeloma who have received 4 prior lines of therapy. From @medicalprofref.bsky.social.

bit.ly/44DaAU7

Long-Term Hydroxyurea Use Effective in Children With SCD Researchers determined long-term use of hydroxyurea is effective in children with SCD.

Long-term treatment with hydroxyurea has sustained clinical benefits, including reduced emergency department visits and hospital days, for children living with #sickleCellDisease. Published in @bloodadvances.bsky.social.

bit.ly/4kllUtD

#SCD

Polatuzumab Vedotin Improves PFS, OS in Rel/Ref DLBCL - Hematology Advisor Results from the POLARGO trial “reinforce the benefit of adding polatuzumab to chemoimmunotherapy,” said Matthew Matasar, MD.

Adding polatuzumab vedotin to treatment with R-GemOx can improve survival outcomes in patients with R/R diffuse large B-cell #lymphoma. Presented at @hemasphere-journal.bsky.social #EHA2025.

bit.ly/4lLWJSn

#DLBCL #lymphsm

Psychological Stress Biomarker Levels Found Higher in Neuro-Oncology Caregivers Researchers found that C-reactive protein is a biomarker for psychological stress in caregivers of patients with primary malignant brain tumor. C-reactive protein levels were found to be a biomarker o...

C-reactive protein levels are found to be increased among #caregivers of persons with a primary malignant #braintumor, highlighting the role of this biomarker as an indicator of psychological stress. Published in @oncologynurseadv.bsky.social.

bit.ly/4lFdONA

#CancerCare

Salvage High-Dose Chemotherapy Plus ASCT, Lenalidomide Not Recommended in Relapsed, Refractory MM Researchers determined salvage high-dose chemotherapy, ASCT, and lenalidomide maintenance does not appear to improve OS outcomes in relapsed/refractory MM.

Among patients with R/R #multipleMyeloma, a therapeutic combination including salvage high-dose chemotherapy, ASCT, and lenalidomide maintenance does not appear to improve OS outcomes. Published in @bloodadvances.bsky.social.

bit.ly/44Dio8i

Personalized Algorithm May Aid in HDMTX Infusion in Pediatric ALL - Oncology Nurse Advisor Researchers sought to determine whether a real-time personalized algorithm may help to effectively plan HDMTX infusion among pediatric patients with ALL.

A real-time personalized algorithm may help to effectively plan HDMTX infusion among pediatric patients with acute #lymphoblasticLeukemia in non-optimal clinical settings. Published in @ascocancer.bsky.social journal JCO Global Oncology and @hematologyadvisor.bsky.social.

bit.ly/3ZoFmy6

#leusm

Caregiver Perceptions of Hope and Child Self-Regulation in SCD and Cancer - Oncology Nurse Advisor Researchers compared feelings of hope in caregivers of children with SCD and children with cancer.

A pilot study involving the experiences of caregivers suggests that those caring for children with #sickleCellDisease had felt a greater sense of hope than did those caring for children with cancer. From @hematologyadvisor.bsky.social.

bit.ly/43NGUED

#SCD

Brukinsa Tablets Get FDA Nod for All Approved Indications The Food and Drug Administration has approved a new tablet formulation of Brukinsa® (zanubrutinib).

The @fda.gov has approved a new tablet formulation of Brukinsa® (zanubrutinib), which is expected to replace the current capsule formulation in October 2025. From @medicalprofref.bsky.social.

bit.ly/45xrR3b

#lymphoma #lymsm

Hemophilia B Gene Therapy Demonstrates Long-Term Efficacy and Safety Researchers determined a single administration of gene therapy for hemophilia B resulted in durable factor IX expression long term.

A 13-year follow-up study has demonstrated that a single administration of gene therapy for #hemophilia B resulted in durable factor IX expression, sustained clinical benefit, and no late-onset safety concerns. From @nejm.org.

bit.ly/4e2LfXI

ASPHO 2025: Patients, Parents, and Oncologists Agree Prognosis Conversations Can Allow for Hope - Hematology Advisor A RIGHTime study involving pediatric patients, parents, and oncologists believe that honest discussions on prognosis can support hope.

Patients and parents preferred their #oncologist provide options and recommend a plan, even if no cure is available. Presented at American Society of Pediatric Hematology/Oncology conference #ASPHO2025, from @oncologynurseadv.bsky.social.

bit.ly/3FZ2VHk

A short duration of anticoagulation therapy, of 3 to 6 months, was identified as potentially beneficial in comparison to a longer course, for primary treatment of #VTE. Reported in @ash.hematology.org journal Blood Advances.

bit.ly/44h3T9U

In the setting of pregnancy, patients with #sicklecelltrait appeared more likely to experience pyelonephritis/#UTI than women without SCT. Reported in @ash.hematology.org journal Blood Portfolio.

bit.ly/45kQC2m

The addition of dasatinib to intensive induction and consolidation chemotherapy and maintenance failed to improve outcomes among patients with CBF-#AML. Presented at European Hematology Association conference #EHA2025.

bit.ly/4lrJxSw

#leusm

Early Neutrophil Count Predicts Mortality in Older Patients With SAA Extremely low baseline neutrophil count was a strong predictor of early death, underscoring the need for early risk stratification.

Extremely low baseline neutrophil count was a strong predictor of early death, underscoring the need for early risk stratification. From @rarediseaseadvisor.bsky.social.

bit.ly/4dFaejJ

#anemia